[Form 4] Disc Medicine, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Georges Gemayel, a director of Disc Medicine, Inc. (ticker: IRON), was granted a stock option to purchase 1,000 shares of common stock on 09/16/2025 at an exercise price of $60.34 per share. The option is exercisable subject to vesting that occurs on the earlier of the company’s 2026 annual meeting or the one-year anniversary of the grant date, and it expires on 09/15/2035. The filing reports the option as a direct holding and shows 1,000 underlying shares following the transaction.

This Form 4 was submitted by an attorney-in-fact and signed on behalf of the reporting person on 09/18/2025. No other transactions or cash sales are disclosed in the filing.

Positive

• Grant disclosed: The filing clearly reports a stock option grant of 1,000 shares with an exercise price of $60.34.
• Clear vesting terms: Vesting is explicitly stated as the earlier of the 2026 annual meeting or one-year anniversary, providing transparent conditions.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine director stock option grant for 1,000 shares at $60.34, standard multi-year term and time-based vesting.

The grant recorded on Form 4 represents a non-derivative reporting of a stock option with a $60.34 exercise price and a 10-year contractual term expiring 09/15/2035. Vesting is time- and event-based, occurring on the earlier of the 2026 annual meeting or one year from grant, conditional on continued service. From a disclosure standpoint this is a standard equity compensation event for a director and does not indicate any exercised or disposed shares or immediate cash proceeds. Impact on shareholder dilution is minimal at 1,000 shares unless combined with other outstanding awards.

Corporate Governance Expert

TL;DR: Typical director option award with one-year or meeting-based vesting, documented and filed via Form 4.

The filing cleanly documents beneficial ownership change for a director-level reporting person and includes a clear vesting condition tied to continued service and a corporate event (annual meeting). The use of an attorney-in-fact signature is noted and properly dated. The disclosure contains no unusual acceleration clauses or immediate transfers; it therefore aligns with routine governance practices for board member equity awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

GEMAYEL GEORGES

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$60.34	09/16/2025		A		1,000		(1)	09/15/2035	Common Stock	1,000	$0	1,000	D

Explanation of Responses:

1. The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2026 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

	/s/ Rahul Khara, attorney-in-fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Disc Medicine (IRON) disclose in this Form 4 for Georges Gemayel?

The Form 4 reports a stock option grant of 1,000 shares at an exercise price of $60.34, granted on 09/16/2025, expiring 09/15/2035.

When do the shares underlying the option vest for the reporting person?

The shares vest on the earlier of the company’s 2026 annual meeting or the one-year anniversary of the grant date, subject to continued service.

Does the Form 4 show any exercised or sold securities by the reporting person?

No. The filing shows only an option acquisition and records 1,000 underlying shares as beneficially owned following the transaction.

Who signed and filed the Form 4 for Georges Gemayel?

The form was signed on behalf of the reporting person by Rahul Khara, attorney-in-fact on 09/18/2025.

What is the expiration date of the option reported on the Form 4?

The option expires on 09/15/2035.